驱动基因共突变的NSCLC患者,免疫治疗该何去何从
1 常见的NSCLC的基因共突变类型有哪些?
2 不同类型基因共突变的免疫微环境特征和对免疫治疗的影响
KRAS-LKB1共突变型(KL型)
KRAS-KEPA1-(LKB1)共突变型
KRAS-TP53共突变型(KP型)
KRAS-MYC共突变型
DDR基因共突变型(HRR-BER或HRR-MMR共突变)
3 小结
1. Skoulidis F, Heymach J V, et al. Co-occurringgenomic alterations in non-small-cell lung cancer biology and therapy[J].Nature reviews. Cancer, 2019, 19(6411).
2. KoyamaS, Akbay E A, Li Y Y, et al. STK11/LKB1 Deficiency Promotes NeutrophilRecruitment and Proinflammatory Cytokine Production to Suppress T-cell Activityin the Lung Tumor Microenvironment[J]. Cancer Research, 2016, 76(5).
3. Skoulidis,F. et al. Association of STK11/LKB1 genomic alterations with lack of benefitfrom the addition of pembrolizumab to platinum doublet chemotherapy in
non- squamous non- small-cell lung cancer[J].Clin. Oncol. 37, (15 Suppl.) 102 (2019).
4. Ferdinandos S, MichaelE, Goldberg, Danielle M, et al. STK11/LKB1 Mutations and PD-1 InhibitorResistance in KRAS -Mutant Lung Adenocarcinoma[J]. Research Article, 2018, 8(7):794-796.
5. KortleverR M, Sodir N M, Wilson C H, et al. Myc Cooperates with Ras by ProgrammingInflammation and Immune Suppression[J]. Cell, 2017, 171(6):1301-1315.e14.
6. Jie W,Zhijie W, Jing Z, et al. Co-mutations in DNA damage response pathways serve aspotential biomarkers for immune checkpoint blockade[J]. Cancer Research, 2018: canres.1814.2018-.